The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
about
Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: An up-to-date meta-analysisRate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes.Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent RegimensPrognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports.Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis.Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma.Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Prognostic role of the lymphocyte-to-monocyte ratio in patients undergoing resection for nonmetastatic rectal cancer.High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma.Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy.Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphomaPrognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis.Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer/T-cell lymphoma.
P2860
Q33662640-591A0A98-1A94-4588-8426-48758B286D1CQ33701858-15822A79-DBE5-491B-AB70-FF321EC0B7F0Q33765560-FE1AB0A5-F14F-4C8F-9DBD-DC692107813EQ34257135-B9903C66-50CC-4AC3-8E41-8CCCFF262641Q36194582-D25F1AF0-918F-44D5-B539-ED8648DC5960Q36540944-159E83BC-0DA6-4A23-925B-212BC5D6DC87Q36673451-D4D2DE7D-AF73-48C8-B1AD-88BD33F48A2EQ36940100-A8E4BBA3-AFDE-465F-8E5F-D31BAE7B453DQ37362567-030BD156-B2D4-4014-94C7-5F69A1B431A8Q37375247-3CF896AD-4DD4-4AEE-9FA6-48E97BA11ECAQ37706368-7528DBDE-FD64-4209-AFAE-EB03E40ECBEDQ37746065-1A6C5AC7-D5DC-4F67-9576-76B11C5E5CB0Q38897604-FBD6D7C0-6A39-46AC-8432-F1C28E10BE1CQ40470497-C0E066C9-D1CF-4932-A54D-F5B3963B927BQ41120596-EC101354-74B6-4AAD-BF3F-FA8D6DA0729EQ41171241-D6FA1584-3E1F-4FDF-B131-EB970ECCD328Q41428549-E5D2732A-23BB-45A4-A20F-7B9E4DE72AF6Q41471302-5D367587-39C6-4970-B4E5-4258E5871610Q43114005-8DA6DD3F-E0AD-4233-8946-2908071F62E4Q43754838-507998F5-3236-4AD4-A2E0-490170AB0920Q45216334-31B54470-6BD0-4A6A-8EFA-EDDA15C054ABQ48654812-79555F2D-B6E9-442E-B22B-5EF89D741D5C
P2860
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@en
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@nl
type
label
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@en
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@nl
prefLabel
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@en
The lymphocyte to monocyte rat ...... imab is added to chemotherapy.
@nl
P2093
P2860
P50
P356
P1476
The lymphocyte to monocyte rat ...... ximab is added to chemotherapy
@en
P2093
Alberto De Crescenzo
Alessandro Massimo Gianni
Alessandro Rambaldi
Andrea Rossi
Anna Maria Barbui
Caterina Patti
Corrado Tarella
Daniele Caracciolo
Elena Oldani
Federica Delaini
P2860
P304
P356
10.1002/AJH.23566
P577
2013-09-30T00:00:00Z